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ABSTRACT
Background BNT162b2, an mRNA COVID-19 
vaccine, was launched in many countries as an intra-
muscular vaccination for COVID-19 infection. Few 
studies have assessed the physical indications of pain at 
the immunization site. This study aimed to characterize 
pain at the injection site and investigate morphological 
attributes using ultrasound.
Methods Forty-three of 211 healthcare workers who 
received a second dose of BNT162b2 between February 
2021 and March 2021 were enrolled in the study. The 
mean age of the subjects was 40 years. We evaluated 
patients’ pain at the injection site using the Numerical 
Rating Pain Scale (NRPS). We also assessed the thick-
ness of the deltoid muscle fascia at the injection site by 
ultrasound. Bayesian robust correlation was employed 
to explore the relationship between the pain intensity 
scores and ultrasound measurements.
Results All eligible subjects complained of pain at 
the injection site. A median pain onset of 8 hours post-
vaccination and a median peak intensity score of 4 
were reported. Onset of relief occurred after 2 days. 
Ultrasound images demonstrated a 2.5-fold increase in 
fascia thickness at the injection site without intramus-
cular echogenicity change in all subjects. A correlation 
was established between the NRPS score and the non-
injection-to-injection-side ratio of fascia thickness at the 
injection site (rho = 0.66).
Conclusion A sore arm was the most prevalent side 
effect of BNT162b2 vaccination and could be attributed 
to temporal fasciitis.
Key words COVID-19: fasciitis; intramuscular injec-
tion; vaccination
Coronavirus disease-19 (COVID-19), caused by the 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), has emerged as a severe global pan-
demic.1 The pandemic has resulted in unprecedented 
medical, social, and economic damage globally with 
more than 100 million people infected and over 2,750,000 
deaths as of April 1, 2021.2 Developing vaccines against 
SARS-CoV-2 is critical to eradicating the COVID-19 
pandemic. As of February 18, 2021, at least seven differ-
ent vaccines across three platforms have been rolled out 
in various countries.2
One of these vaccines is the lipid nanoparticle 
(LNP)-formulated, nucleoside-modified RNA vac-
cine BNT162b2 (Pfizer–BioNTech, NY, and Mainz, 
Germany), which encodes a membrane-anchored 
SARS-CoV-2 full-length spike protein stabilized in the 
perfusion conformation. Polack and colleagues reported 
an efficacy of 94.8% against COVID-19 after two doses 
of the messenger RNA (mRNA) vaccine BNT162b2.3 
The most common side effect of the BNT162b2 vaccine 
is pain, especially when touched, at the site of intramus-
cular injection. Of trial participants aged 16 to 55, 83% 
reported pain at the injection site after the first dose, 
whereas 78% reported pain after the second dose.3
Here, we investigate this seemingly characteristic 
pain at the injection site, including time before onset, 
duration, and pain intensity. Considering the increased 
use of ultrasonography in the evaluation of muscle 
conditions, including damage and inflammation, over 
the years, we also performed an ultrasonographic as-
sessment of the injection site after vaccination.
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MATERIALS AND METHODS
Study design
Out of 478 healthcare workers at the Yonago Medical 
Center, 377 had received the first of two doses of 
the BNT162b2 vaccine on February 19, 2021, and a 
questionnaire of adverse effects was obtained from 284 
subjects. In our pilot study of the first vaccination, 92% 
of those vaccinated complained of pain at the injection 
site, with the peak of pain at 24 hours after the injection. 
The two shots were to be administered 3 weeks apart. 
The present study included the subjects who received 
the second vaccination dose.
The inclusion criteria were as follows: (1) aged 20 
years or more; (2) his/her schedule matched up with our 
work shift for ultrasound assessment after 24 hours of 
the injection, and (2) his/her consent to participation 
was obtained. This study was approved by the Ethics 
Committee of Yonago Medical Center (Ethical Code 
No.: 0303-01). Written informed consent was obtained 
from all participants after they were briefed on the 
purpose and procedures of the study.
Intramuscular injection protocol
The COVID-19 mRNA BNT162b2 vaccine was sup-
plied after dilution with saline to a total volume of 0.3 
mL. In the usual method, after selecting the injection 
site, three finger breadths (5 cm) below the mid-
acromion skin is retracted with the thumb and index 
finger.4 The 25-gauge needle is then inserted through 
the muscle using the dart technique for intramuscular 
injection at a 90° angle. The second dose of the vaccine 
was administrated at close 3-week interval after the first 
dose of the vaccine in the same arm.
Assessment of pain at the injection site
To characterize pain at the injection site, data were col-
lected using a paper-based questionnaire. The first part 
of the questionnaire included demographic data (age 
and sex) and the second part requested information on 
onset, duration, and intensity. Evaluation was performed 
using the Numeric Pain Rating Scale (NPRS) to obtain 
a descriptive rating of the injection pain intensity. The 
NPRS is a unidimensional measure of pain intensity in 
adults.5–7 The 11-point numeric scale ranges from “0,” 
representing no pain, to “10,” representing worst pos-
sible pain.6, 7
Ultrasound evaluation of the deltoid muscle
Images of the injection site were obtained by B-mode 
ultrasonography (Xario 100G ultrasound, Canon 
Medical Systems Corporation, Ohtawara city, Japan) 
using a high-resolution linear array 7.5 MHz probe (38 
mm). A single high-resolution, short-axis ultrasound 
(US) image of the deltoid muscle at the injection site 
was taken for each patient. We further assessed the im-
ages by comparing the injection site to the contralateral 
side, which served as normal control. All images were 
de-identified by a radiologist not involved in the blinded 
review of the images, and the images were assigned 
random numbers. These individual de-identified and 
numbered images were then reviewed blindly by two 
other physicians.
Statistical analysis
Categorical variables were computed as sums and per-
centages, whereas continuous variables were expressed 
as means and SDs and/or range and median and inter-
quartile range (IQR).
In a classical Pearson’s correlation test in which the 
data followed a bivariate normal distribution, serious 
outliers can lower the estimated correlation coefficient. 
On the other hand, Bayesian robust correlation analysis 
can be made robust to outliers by replacing the bivari-
ate normal distribution with a bivariate Student’s t-
distribution.8 In this study, Bayesian robust correlation 
analysis was used to evaluate the association between 
the pain intensity scores and ultrasound measurements. 
All statistical analyses were performed using the proba-
bilistic programming language Stan (version 2.26)9 us-
ing the statistical package R (version 3.6.3. 2020, The R 
Foundation for Statistical Computing, Vienna, Austria). 
Stan is built upon the Hamiltonian Monte Carlo (HMC) 
algorithm, part of the Markov Chain Monte Carlo 
(MCMC) family of algorithms10 that samples efficiently 
from the posterior distribution of the correlation coef-
ficient (rho). The code for the analysis is publicly avail-
able on the website.11
RESULTS
Subject characteristics
Two hundred and eleven healthcare workers at the 
Yonago Medical Center received the second dose of 
BNT162b2 vaccine, and were registered as question-
naire participants. Injection site pain (91%), injection site 
erythema (18%), and fever (32%) were the most frequent 
adverse events reported. Due to contradiction between 
ultrasound assessment and our work-shift timing, a final 
total of 43 subjects were eligible for further analysis. 
The mean age was 40 years (range 21–77 years), and 
70.6% of the study population were female.
Onset, duration, and intensity of injection site pain
Median onset was 8 hours (range 2–24 hours) after the 
vaccination, and onset of relief occurred after a median 
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of 56 hours (range 24–144 hours) post-vaccination. 
Median pain duration was 2 days (range 0.4–5.8 days) 
and the median peak intensity score was 4 (range 1.5–6) 
(Fig. 1B). In eleven participants (25%), non-steroidal 
anti-inflammatory drugs (NSAIDs) were used as pain 
and fever relievers.
When intramuscular injection of 1 mL saline into 
the deltoid muscle was performed in three volunteers 
of eligible participants two weeks after the second dose 
of the vaccine, the median onset was 10 min, and the 
median duration was 30 min. The peak intensity score 
was 2 (range 1.5–2) (Fig. 2B).
Musculoskeletal ultrasound imaging
Sonograms were retrospectively assessed with respect 
to echogenicity (hypoechoic, isoechoic, or hyperechoic 
relative to uninvolved muscle), distribution of muscle 
involvement, and intramuscular pattern (focal versus 
diffuse and well defined versus poorly defined). No dif-
ferences were observed in echogenicity, muscle involve-
ment, and intramuscular pattern between the injection 
site and the contralateral side.
In order to determine a timecourse of change 
on ultrasound, three volunteer subjects were scanned 
at 0, 1 day, 2 days, 3 days, 5 days, and 7 days after 
administration of the second vaccination dose. Fascia 
thickness was indicated on the injection site of the del-
toid muscle, peaking at 1 day post-vaccination (Figs. 1A 
and B). After confirming a time schedule for ultrasound 
schedule, in all the other subjects (n = 40), ultrasound 
imaging was performed 1 day after the vaccination. As 
fascia thickness is independent of age,12 we assessed 
fascia thickness bilaterally, and the difference between 
the fascia thicknesses of both sides was indicated as the 
non-injection-to-injection-side ratio. The non-injection-
to-injection-side ratio of fascia thickness 24 hours 
after vaccination was 2.5 (range 1.4–5.7) in all eligible 
subjects (n = 43).
Conversely, when 1 mL saline was injected into 
the deltoid muscle, the non-injection-to-injection side 
ratio of fascia thickness was 1.0–1.1 in three healthy 
volunteers (Figs. 2A and B).
Bayesian robust correlation analysis
The posterior density of the correlation coefficient (rho) 
was obtained to determine the association between the 
NRPS score and the non-injection-to-injection-side ratio 
of fascia thickness at the injection site. We used a burn-
in of 500 steps, and then ran HMC for an additional 1,500 
steps. The convergence of the HMC was confirmed 
based on all variables with Gelman–Rubin convergence 
statistic < 1.1. In addition, simulation values were found 
stable on a trace plot (Fig. 3A) and a marginal density 
plot (Fig. 3B). With MCMC convergence assured, point 
estimates and 95% confidence intervals of probability 
were retrieved for computing posterior quantiles and 
plotting the posterior density of rho. The Bayesian 
robust correlation obtained rho = 0.66 (range 0.45–0.81) 
with 99% probability (Fig. 3C).
Fig. 1. A representative longitudinal ultrasound image of the 
deltoid muscle at the injection site at one day after intramuscular 
BNT162b2 vaccine (A). Two callipers have been placed to mea-
sure fascia thickness (arrows). Differences in the pain intensity, 
the non-injection-to-injection-side ratio of fascia thickness (rate) 
in the timecourse after the injection, and the ultrasound images 
of the injection site in three volunteer subjects who were adminis-
tered intramuscular BNT162b2 vaccine (B).
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DISCUSSION
In this study, transient immunization site pain was 
assessed using validated pain intensity, measured on 
NPRS. Arm pain at the intramuscular injection site 
occurred 8 hours after administration of the second 
dose of the BNT162b2 mRNA COVID-19 vaccine and 
lasted for 2 days with the pain intensity of 4 as NPRS. 
Ultrasound images suggest that pain at the injection site 
might be due to transient fasciitis.
Intramuscular injection is a common technique of 
delivering medication,13, 14 and side effects of pain and 
discomfort in patients are often described. The results 
of one study showed that 40% of patients who received 
intramuscular injections described their experience as 
very painful.15 Regarding vaccinations by intramuscular 
delivery, 13-valent pneumococcal conjugate vaccine 
(PCV13)16 and Shingrix, a recombinant zoster vaccine 
(RZV),17 had injection site pain incidence rates of 24% 
and 79.1%, respectively. In the present study, 96% of the 
subjects who received a second BNT162b2 intramuscu-
lar injection complained of pain at the injection site. The 
onset of pain began 8 hours after the vaccination, and 
continued for 2 days.
In our study, intramuscular injection of saline 
contributed to an immediate hyperechoic lesion at the 
Fig. 2. A representative longitudinal ultrasound image of the 
deltoid muscle at the injection site at 20 minutes after 1.0 mL of 
saline (A), and differences in the pain intensity, the non-injection-
to-injection-side ratio of fascia thickness (rate) in the timecourse 
after the injection, and the ultrasound images of the injection site 
in three healthy volunteers who were administered intramuscular 
saline injection (B).
Fig. 3. (A) Trace plot, (B) marginal density plot of rho, and 
(C) correlation between pain intensity and measurement of 
fascial thickness, which is representative as the non-injection-
to-injection side ratio. Trace plots of Markov chain Monte Carlo 
(MCMC) using Hamiltonian dynamics showed the history of a 
parameter value across 2,000 (iterations) simulations of the pro-
cedure. Marginal density plot of Bayesian posterior probability 
is the smoothened histogram of the values of rho and shows the 
posterior distribution of the correlation coefficient (rho) as the 
parameter.
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injection site in the deltoid muscle, which spontane-
ously regressed within one hour after the vaccination, 
without fascia thickness. The acute muscle edema may 
be related to the extravasation of protein-rich fluid to the 
damage/injury site, which occurs due to an increased 
membrane permeability of small blood vessels.18 On 
the other hand, we found a significant 2.5-fold increase 
in thickness of the deltoid muscle fascia in the subjects 
who received BNT162b2 vaccine. Based on previous 
measurement errors of 3%–5% determined in fascial 
tissues,19 this ratio was significant. This finding was 
similar to those observed in patients with dermato-
myositis (DM) and polymyositis (PM).20 Some reports 
provide evidence that fasciitis in the deltoid muscle is 
involved in the pathogenesis of DM/PM and is associ-
ated with patient symptoms of myalgia.21, 22
In this study, we showed positive relationship be-
tween pain intensity and measurement of fascial thick-
ness. A statistical correlation was reported between pain 
and fascial thickness in patients with upper trapezius 
myofascial pain syndrome.23, 24 Patients who received 
the BNT162b2 vaccine have also reported increased 
rates of palpable unilateral lymphadenopathy at axillary 
lymph node, which was usually resolved within 10 days 
post-injection.25 The local response with pain might be 
demonstrated as temporal fasciitis at the injection site 
of the deltoid muscle due to drain the produced antigens 
from the injection site to the axillary lymph node.26
The limitations of this study included a small 
sample size and variation. Further studies are required 
and must involve a larger number of samples and dif-
ferent age groups, ensuring ample representation of the 
elderly. Another potential limitation is self-selection 
bias by the use of data collected only from subjects who 
decided to enroll in the study. However, this bias was 
limited in this study, because the statistics from the 
registered participants (n = 211) equaled the eligible sub-
jects (n = 43) parameter as mean age, sex, and adverse 
effects including fever and headache. Furthermore, our 
study had no pathological findings of temporal fasciitis. 
Future investigations should also explore for evidence of 
local reactions in the muscle fascia.
Based on the results of the present study, transient 
pain at the site of intramuscular BNT162b2 vaccine was 
predominantly reported, with pain lasting for 2 days. 
This side effect could be attributed as temporal fasciitis. 
Future studies clarifying the possible pathological im-
pact of fasciitis at the injection site are recommended.
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